U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06869174) titled 'Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary' on March 05.
Brief Summary: This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.
Study Start Date: March 08
Study Type: INTERVENTIONAL
Condition:
Cancer of Unknown Primary
Intervention:
DRUG: Pucotenlimab combined with MRG002
Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Zhiguo Luo, MD, PhD
Inform...